Medicaid Mental Health Improvement: Genetic Testing for Depression Treatment.
This bill aims to improve treatment outcomes for Medicaid beneficiaries suffering from major depressive disorder and other mental health conditions. It mandates the issuance of guidance to State Medicaid programs on utilizing pharmacogenetic testing. This measure allows doctors to select effective medications faster, significantly reducing the trial-and-error period for patients.
Key points
CMS must issue guidance on covering pharmacogenetic testing for treating depression and mental health conditions under Medicaid.
Medicaid beneficiaries gain access to more precise and potentially faster treatment by minimizing ineffective medication trials.
Expired
Citizen Poll